Overview

Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
0
Participant gender:
All
Summary
The goal of this clinical research study is to learn if a special combination of chemotherapy drugs called "augmented hyper-CVAD chemotherapy" given over 6 to 8 months followed by monthly maintenance chemotherapy for one year can help to control acute lymphoblastic leukemia or lymphoblastic lymphoma. The safety of this therapy will also be studied.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Enzon Pharmaceuticals, Inc.
Treatments:
Asparaginase
BB 1101
Cyclophosphamide
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Doxorubicin
Liposomal doxorubicin
Methotrexate
Pegaspargase
Vincristine
Criteria
Inclusion Criteria:

- Previously treated acute lymphoblastic leukemia (ALL) (including Burkitt's lymphoma)
or lymphoblastic lymphoma in relapse or primary refractory;

- No age restrictions;

- Zubrod performance status
- Adequate liver (bilirubin function (creatinine
- Adequate cardiac function (New York Heart Association (NYHA) < III as assessed by
history and physical examination)

Exclusion Criteria:

- Not Applicable